Recently, Hong Kong-listed AI science intelligence leader XTALPI (02228) released a profit warning for the first half of 2026, forecasting a swing from profit to loss for the period. While the profit alert has stirred short-term market concerns, an analysis of the announcement reveals the company's underlying logic remains intact. Investors can clearly see that the profit fluctuation is not due to weakness in the core business, but stems from two objective factors: first, the comparison base was elevated by a one-time, large-scale licensing deal worth $51 million from the Dovetree project in the same period last year; second, the company has proactively increased its R&D investment. In fact, after excluding the one-time licensing revenue from Dovetree, XTALPI's core business showed strong endogenous growth momentum, with a year-on-year increase of over 65%. Specifically, its AI for Science segment grew by more than 120% year-on-year. Furthermore, with the imminent launch of its comprehensive scientific research open platform, XtalPi Science, and the continuous construction of exclusive scientific data assets to build core barriers, XTALPI's long-term growth logic remains unchanged. Its R&D platform capabilities, spanning multiple business segments, continue to be validated and deliver value in the fields of small molecule drugs, peptides, antibodies, small nucleic acids, and new materials.
Short-term accounting base disturbances do not challenge the resilience of the core business foundation. On August 5 last year, XTALPI and DoveTree reached a pipeline collaboration with a total order size of approximately $5.99 billion, setting a new record for order scale in the AI-driven drug discovery (AIDD) field. An upfront payment of $51 million from DoveTree was recognized as revenue by XTALPI in the first half of 2025, a key driver behind its revenue surge of over 200% last year and its first-ever annual profit. According to XTALPI's disclosures, following the normal pace of cooperation, further payments from DoveTree will be recognized in batches by the company. A second payment of $19 million, received in May this year, was recognized as mid-term revenue. The mismatch in the timing of revenue recognition from the collaboration and XTALPI's own financial reporting cycle directly caused the period's reported revenue to appear weaker year-on-year. In short, the company's current financial data changes are merely short-term accounting base disturbances and cannot accurately reflect its normalized operational strength. After excluding all one-time payments related to Dovetree, XTALPI's endogenous revenue for the period grew by over 65% year-on-year, with its AI automated robotics laboratory and intelligent services business achieving a growth rate of over 120% for the period. Additionally, during the period, XTALPI not only secured stable recurring revenue from traditional small molecule drug discovery R&D services and maintained a steady delivery pace for collaboration orders from top global pharmaceutical companies, but also saw the continued implementation of new projects from domestic and international Biotech and new materials companies. The clear acceleration and improvement in core business indicators not only confirm the accelerated penetration of the AI for Science industry but also validate the strong resilience of XTALPI's main business foundation.
If XTALPI's own high business growth proves its hard power, then the rapid advancement of AI large model technology and the significant reduction in costs have pressed the accelerator for the entire industry. Technologically, AI's capabilities in core drug R&D stages have markedly improved. According to industry forecasts, advanced protein structure prediction models have achieved over 50% improvement in accuracy compared to traditional methods, and this technology is moving from the lab to practical application. Even more noteworthy is the cost side. Over the past two years, while the capabilities of mainstream large models have significantly improved, computational costs have continued to decline. This means that AI R&D tools are becoming accessible to small and medium-sized biotech companies, new materials enterprises, and even academic institutions at a lower cost. As the customer base expands from "a few top-tier players" to the "long tail of the majority," the market ceiling for leading reusable platform companies like XTALPI is significantly raised. For investors, a key signal is this: when the cost of using core technology enters a rapid decline phase, industry penetration rates often break through a critical point soon after, ushering in a period of explosive growth. XTALPI's current high growth is supported not only by its own capabilities but also by the underlying logic of dividends from the entire industry's technological transformation. Its ample cash reserves and sustained R&D investment further provide abundant ammunition and momentum for the next growth cycle.
Actively paying strategic costs to accelerate into the "technology compound interest period". Although XTALPI has been the first to successfully run a commercial closed loop in recent years, more significant than short-term profit figures is the company's strategic core of "technology first." As a leader in AI for Science, XTALPI has chosen to increase R&D investment, aiming to transform the multiplier effect of its "AI + Robot" platform into sustainable competitiveness. The financial report shows that XTALPI's R&D expenses for the period increased by approximately 50% year-on-year, with investments focused on the medium- to long-term strategic layout of AI for Science. The company's main investment directions are threefold: constructing autonomous laboratories, building intelligent agent systems, and advancing new drug technology platforms and self-developed pipelines, continuously amplifying the value of the company's innovative technology. From the perspective of industrial evolution, AI for Science is transitioning from "single-point tool assistance" to a qualitative stage of "intelligent agent-driven, full-process closed loop." The leap in large model capabilities means AI is no longer limited to optimizing efficiency in a single step but can permeate the entire chain from target discovery, molecular design, and synthesis route planning to experimental validation. XTALPI's forward-looking deployment of autonomous laboratories and intelligent agent systems is essentially about seizing the commanding heights of the next-generation scientific research infrastructure of "large models + robots." As model invocation costs continue to decline, the unit R&D output cost curve for AI for Science is rapidly shifting downward, signaling that the commercialization inflection point has arrived. When a technology platform transitions from "proof of concept" to "scalable revenue contribution," the market is willing to grant a significant valuation premium. XTALPI's current R&D investment is essentially stockpiling ammunition for the upcoming "technology compound interest period." The pressure on short-term profits is exchanged for room to restructure the medium- to long-term valuation system. In fact, looking at the past financial performance of domestic and international peers, high-intensity R&D investment and periodic losses are the norm in the current stage of the AI science intelligence industry. As one of the few AI platforms in the AI application track that has achieved profitability in the past, XTALPI's advantage lies in its ample cash on hand, providing a safety cushion to implement counter-cyclical technology layout. By proactively paying strategic costs, it can accelerate its entry into the "technology compound interest period." From a policy perspective, AI-empowered scientific research has been elevated to a national-level strategy in both China and the US, with industry sentiment continuously rising. Heavy investments from both the government and the industrial side mean the long-term development space for the track is highly certain. From an industry perspective, AI has also moved beyond the proof-of-concept stage and fully entered the cycle of scaled commercial application. Therefore, at this critical juncture when the global AI industry is transitioning from early exploration to a period of rapid penetration, XTALPI's upfront investment is expected to accelerate its market share capture. With the upcoming launch of the XtalPi Science platform on July 29 and its subsequent implementation, XTALPI's medium- to long-term performance growth is expected to flourish from multiple fronts, sustaining its high growth trajectory.
In conclusion, during this period of deep transformation in the AI industry, XTALPI is accelerating the effective conversion of its technological investments into global competitiveness. Looking ahead to the next 6-12 months, the company faces a window of intensive catalysts: the commercial rollout of the XtalPi Science platform, milestone progress on more pipelines, and the disclosure of potential large-scale collaboration orders could all serve as triggers for valuation re-rating. In 2026, as AI vertical applications move from "theme speculation" to "earnings delivery," XTALPI is currently at an inflection point of expectation divergence between "short-term report pressure" and "long-term value leap." This presents a strategic window for positioning in the science intelligence track. As multiple positive catalysts are subsequently realized, the company's business growth is expected to accelerate, showcasing considerable upward elasticity to market investors as a core allocation target for long-term investment in the science intelligence track.
Comments